Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03817970 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cisplatin Disposition and Kidney Injury

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Final enrollment: 45 participants (planned 72) Eligibility criteria expanded, about 18 words · Publications: 4 to 3 Show 2 more changesShow less
    • Eligibility criteria expanded, about 18 words
    • Publications: 4 to 3
  2. Primary completion date: Sep 30, 2025 to Sep 30, 2027 Completion date: Dec 31, 2026 to Dec 31, 2027v15 Show 1 more changeShow less
    • Completion date: Dec 31, 2026 to Dec 31, 2027
  3. Collaborators: 2 to 3v14 See this version in full on ClinicalTrials.gov ↗
  4. Collaborators: 3 to 2v13 See this version in full on ClinicalTrials.gov ↗
  5. Trial status: Recruiting to Active, Not Recruiting Site details revised at 2 of 2 sitesv12 Show 1 more changeShow less
    • Site details revised at 2 of 2 sites
Show 10 earlier versionsHide 10 earlier versions
  1. Site details revised at 2 of 2 sites Eligibility criteria shortened, about 5 wordsv11 Show 1 more changeShow less
    • Eligibility criteria shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study Status, Referencesv10
  3. Phase: Not applicable to Phase 3 Primary completion date: Sep 30, 2023 to Sep 30, 2025 · Start date: Jun 26, 2019 to Nov 15, 2019 · Completion date: Dec 31, 2024 to Dec 31, 2026v9 Show 3 more changesShow less
    • Primary completion date: Sep 30, 2023 to Sep 30, 2025
    • Start date: Jun 26, 2019 to Nov 15, 2019
    • Completion date: Dec 31, 2024 to Dec 31, 2026
  4. Primary completion date: Sep 30, 2022 to Sep 30, 2023 Completion date: Dec 31, 2022 to Dec 31, 2024v8 Show 1 more changeShow less
    • Completion date: Dec 31, 2022 to Dec 31, 2024
  5. 2 versions Re-verified since Aug 27, 2020, no change to tracked fieldsv6-v7
  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Primary completion date: Dec 31, 2022 to Sep 30, 2022 · Start date changed from estimate of Aug 1, 2019 to Jun 26, 2019v5 Show 3 more changesShow less
    • Study sites: 0 to 2
    • Primary completion date: Dec 31, 2022 to Sep 30, 2022
    • Start date changed from estimate of Aug 1, 2019 to Jun 26, 2019
  7. Start date: Jun 1, 2019 to Aug 1, 2019v4
  8. Start date: Apr 25, 2019 to Jun 1, 2019v3
  9. Start date: Jan 25, 2019 to Apr 25, 2019v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.
Trial Details
NCT Number NCT03817970
Lead Sponsor University of Colorado, Denver
Collaborators: Memorial Sloan Kettering Cancer Center, Rutgers University, National Institute of General Medical Sciences (NIGMS)
Conditions Nephrotoxicity
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov